在阿尔茨海默氏病的发病过程中,miR-146a的复杂作用
Yunfan Long1, Jiajia Liu2,3, Yu Wang4
1Department of Neurology, Shanghai No. 9 People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Neural regeneration research
|July 30, 2024
概括
微RNA-146a在阿尔茨海默病中起着双重作用,可能会恶化或改善神经炎症和病理. 需要进一步的研究来探索它对这种神经退行性疾病的治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特征是粉样β斑块和陶,治疗选择有限.
- 微RNA (miRNA) 是调节基因表达的小型非编码RNA,涉及各种生理和病理过程.
- 一个关键的miRNAmiR-146a在AD中显著失调,通过复杂的机制影响疾病的进展.
研究的目的:
- 综合分析miR-146a在阿尔茨海默氏症病原发生中的多方面的作用.
- 阐明miR-146a与AD核心病理之间的关系,包括粉样β沉积,高酸化和神经炎症.
- 审查miR-146a作为阿尔茨海默病诊断标记物和治疗点的潜力.
主要方法:
- 文献综述综合了关于阿尔茨海默氏症中miR-146a的现有研究.
- 对研究miR-146a对粉样β和病理的影响的研究分析.
- 检查miR-146a对神经元功能,线粒体健康,突触可塑性和质细胞活性的影响.
主要成果:
- miR-146a表现出相互矛盾的效应,通过各种信号通路可能减少或加剧粉样蛋白β和蛋白病理.
- miR-146a与突触和线粒体功能障碍,神经元死亡和质细胞改变有关,有助于AD进展.
- 有证据表明,miR-146a可以调节神经炎症,促进髓修复,并在特定情况下产生神经保护作用.
结论:
- miR-146a是阿尔茨海默氏症的关键调节剂,在其发病过程中具有复杂和上下文依赖的作用.
- 了解miR-146a的双重功能对于开发阿尔茨海默病的有效诊断和治疗策略至关重要.
- 对miR-146a通路的进一步研究可能会为这种衰弱的神经退行性疾病提供新的治疗方法.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.9K
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
810
相关概念视频
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
